An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)
The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).
Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD). All study procedures will take place at University Hospital at no cost to you. You will be compensated for your time and effort.
You may be eligible for this study if you meet the following criteria:
- Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
Age: Between 18 Years - 70 Years
Gender: Male or Female
AATD diagnosis, willing to undergo 2 bronchoscopies
Willing to hold current AATD treatment until study ends (about 5 months).